Real-world study of 427 adults, conducted by independent research firm MoreBetter, found participants' pain scores fell 32% within hours of each dose, and 80% said Relief Protab reduced their daily pain SAN FRANCISCO, Sept. 21, 2026 /PRNewswire/ -- LEVEL, a science-driven cannabinoid company, today announced results from an independent 29-day real-world study of its Relief Protab, conducted in partnership with third-party research firm MoreBetter. Across 427 adults with ongoing aches and pain, t

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder and Elbow Surgery (ICSES) in Vancouver from September 22-25. Surgeons are invited to visit the Smith+Nephew booth during ICSES to learn more about the following technologies: TENDON SEAM Rotator Cuff Repair SystemRecently acquired by Smith+Nephew, the TENDON SEAM System is a uniqu

Brings more than three decades of experience leading innovation across the medical technology industryMOUNTAIN VIEW, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce the appointment of Lisa Wipperman Heine to its Board of Directors. Lisa Wipperman Heine brings more than three decades of experience leading

TORONTO--(BUSINESS WIRE)--July Health, a virtual clinic for women aged 18 to 45 facing complex, overlapping chronic hormonal and mental health conditions, today published its inaugural 2026 PMOS Patient Experience & Outcomes Report. Key findings include 90% of patients report improvements in their overall PMOS or hormone-related symptoms, most notably around food noise and binge eating, fatigue, weight management, and blood sugar regulation. The findings, based on an outcomes evaluation of 73 pa

New surgeon-focused program builds on more than 20 years of research as Advita expands its clinical data, with new studies presented at ICSES and ISTA GAINESVILLE, Fla., Sept. 21, 2026 /PRNewswire/ -- Advita Ortho, a global medical technology leader, announces the launch of Axis, a clinical research initiative designed to connect shoulder surgeons with an extensive and growing body of clinical evidence shaping the future of shoulder arthroplasty. Axis is centered around more than 20 years of sho

Since 2016, Edward Jones and its associates have contributed over $63 million to advance Alzheimer's care, support and research Key takeaways Edward Jones and the Alzheimer's Association® are entering the 11th year of their strategic alliance following last year's extension through 2030. As the National Presenting Sponsor of the Walk to End Alzheimer's® since 2016, Edward Jones has raised over $63 million — with nearly 20% directed towards research to end the disease. Edward Jones supports Alzhe

-- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata -- WALTHAM, Mass., Sept. 21, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that additional 36-

Agreement provides for shared stewardship of the open, royalty-free standard for AI operational evidence, with CHAI contributing healthcare expertise and Glacis serving as non-voting editor SEATTLE, Sept. 21, 2026 /PRNewswire/ -- Glacis Technologies, Coalition for Health AI (CHAI) and the AIGovOps Foundation today announced an agreement establishing a framework for the shared stewardship of OVERT (Observable Verification Evidence for Runtime Trust), an open technical specification developed by G

- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile- - First global regulatory approval of obicetrapib marks a defining milestone for NewAmsterdam and Menarini, expanding treatment options for patients with elevated LDL-C - NAARDEN, The Netherlands and MIAMI and FLORENCE, Italy, Sept. 21, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or t

The facility brings Made Scientific's U.S. East Coast footprint to approximately 145,000 sq. ft. and 15 qualified GMP manufacturing suites PRINCETON, N.J., Sept. 21, 2026 /PRNewswire/ -- Made Scientific, Inc., a leading U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO), today announced it has acquired an 85,000 sq. ft. clinical to commercial-scale cell therapy manufacturing facility in East Norriton, Pennsylvania, from National Res